Amrubicin clinical trials
Amrubicin is named as an intervention in 4 current clinical trials in our USA, Germany, France, Spain, Belgium, Brazil, Japan, China, Italy, Netherlands, Poland, Switzerland, Austria, Canada, South Korea, Taiwan, Australia, UK, Czechia, Portugal, Turkey, Mexico, Israel, Ireland, Denmark, Singapore, Norway and Egypt registers. 3 are recruiting patients now. All registered phases are Phase 3. The sponsor with the most trials is Amgen (1). The most-studied condition is Small Cell Lung Cancer.
Where Amrubicin is approved
All regulators →- 1 EU orphan designation, most recently for treatment of small cell lung cancer (2 Apr 2008, withdrawn)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Amrubicin works
All drug targets →- DNA topoisomerase II alpha inhibitor InhibitorTarget: TOP2A DNA topoisomerase II alphaChEMBL only
- Non-small cell lung carcinomaPhase 3
- Small cell lung carcinomaPhase 3
- Breast cancerPhase 2
- Soft tissue sarcomaPhase 2
- Thymic carcinomaPhase 2
- ThymomaPhase 2
- Urothelial carcinomaPhase 2
- Plasma cell myelomaPhase 1/2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1186894, CC BY-SA 3.0. The Guide to Pharmacology has no record of this medicine, so its targets rest on ChEMBL alone. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Amrubicin
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Amrubicin
- ATC code
- L01DB10
- ChEMBL
- CHEMBL1186894
- DrugBank
- DB06263
- PubChem CID
- 3035016
- CAS number
- 110267-81-7
- FDA UNII
- 93N13LB4Z2
- Wikidata
- Q4748723
- Wikipedia
- Amrubicin
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Amrubicin
4 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Amrubicin
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Amgen | 1 |
| Gilead Sciences | 1 |
| Daiichi Sankyo | 1 |
| AbbVie | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Amrubicin trials
How many clinical trials are testing Amrubicin?
4 current trials in our USA, Germany, France, Spain, Belgium, Brazil, Japan, China, Italy, Netherlands, Poland, Switzerland, Austria, Canada, South Korea, Taiwan, Australia, UK, Czechia, Portugal, Turkey, Mexico, Israel, Ireland, Denmark, Singapore, Norway and Egypt registers name Amrubicin as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.
Are Amrubicin trials recruiting patients?
Yes. 3 of the 4 trials are recruiting: 3 with sites in USA, 3 with sites in Germany, 3 with sites in France, 3 with sites in Spain, 3 with sites in Belgium, 3 with sites in Brazil, 3 with sites in Japan, 2 with sites in China, 2 with sites in Italy, 2 with sites in Netherlands, 2 with sites in Poland, 2 with sites in Switzerland, 2 with sites in Austria, 2 with sites in Canada, 2 with sites in South Korea, 2 with sites in Taiwan, 2 with sites in Australia, 1 with sites in UK, 1 with sites in Czechia, 1 with sites in Portugal, 1 with sites in Turkey, 1 with sites in Mexico, 1 with sites in Israel, 1 with sites in Norway and 1 with sites in Egypt. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Amrubicin clinical trials?
Amgen (1), Gilead Sciences (1), Daiichi Sankyo (1) and AbbVie (1). The number in brackets is how many trials each organisation leads.
Are there Amrubicin clinical trials in Ireland?
Yes. 1 trial in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Amrubicin works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Amrubicin works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Amrubicin (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.